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Abstract
Age-related macular degeneration (AMD) is the leading cause of vision loss in
individuals aged 50 years and older and is estimated to affect as many as 11 million
individuals in the United States. The purpose of this study was to examine the association
between vitamin D and AMD disease progression. The life course epidemiology
framework model was used to explore how vitamin D level as a risk factor may have an
association to AMD disease through time. Data in the 2005–2008 National Health and
Nutrition Examination Survey (NHANES) database were collected on vitamin D levels
and identified stages of AMD level based on graded fundus eye exams from an available
sample size of 5,604 participants. A quantitative cross-sectional study approach was used
to address this gap in knowledge. A bivariate analysis was used to examine each
independent variable (age, race/ethnicity, smoking status, and diabetes) to the dependent
variable AMD from the 2005–2008 NHANES dataset. A multivariate logistic regression
analysis was performed with AMD including each independent variable found to be
significant. The findings from this study failed to suggest an association between vitamin
D levels to AMD, with or without the covariates included in the model. There was not an
association found between vitamin D level and presence of AMD. An association was
found between age, smoking, and race to presence of AMD in each of the bivariate
models. The findings from this study could be used for positive social change by
encouraging medical and public health agencies to target screening programs at high-risk
age, smoking, and race groups. There remains to be conflicting data in the literature. This
study adds to the body of literature suggesting that higher levels of vitamin D are not
necessarily beneficial as they pertains to AMD.
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Chapter 1: Introduction to the Study
Introduction
As the term implies, age-related macular degeneration (AMD) refers to macular
degeneration that occurs with age without any other precipitating conclusive associative
risk factors in individuals aged 50 years and older (National Eye Institute [NEI], 2015).
AMD is an ophthalmic condition leading to gradual loss of vision that may not cause
noticeable symptoms in the early stages of the disease. However, through time, blurring
of vision, and loss of sharpness in vision can occur. AMD can result in a wide range of
vision-related symptoms causing impairment that include blurriness, decreased central
vision, distortion of images and lines, decreased intensity or brightness of colors, reduced
night vision, glare or scotoma (blind spot) (NEI, 2015).
Should modifiable factors that are related to AMD development or disease
progression be identified, then there is a potential to have a positive effect on predicted
growing numbers. In Chapter 1, I discuss a review of the existing literature on the topic
of the association of vitamin D levels to AMD and why this association needs to be
explored further. In addition, the research questions and hypotheses that are examined are
stated along with the theoretical framework that was used for the study, discussion of the
nature of the study, assumptions, limitations, terms used in the study are defined, and,
last, how this study will advance knowledge of the AMD disease.
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Background
Several studies have evaluated vitamin D levels and its association with AMD.
Parekh et al. (2007) provided information suggesting that vitamin D might have a
protective effect against AMD. However, Cougnard-Gregoire et al. (2015) found
contradicting results in a population-based sample of French older subjects from a
community dwelling that did not find a specific role for vitamin D in AMD. One notable
difference between these studies was that the former included 7,752 individuals in their
study population compared to 697 subjects in the latter (Parekh, 2007; CougnardGregoire, 2015).
Millen and colleagues (2015) conducted a study that found that vitamin D
deficiency was associated to AMD, with the highest risk in individuals that also
contained 2 risk alleles for complement factor H (CFH) and complement factor I (CFI)
genotypes. Variants in these genes have been shown to be associated with increased
AMD risk – for both early- and late-stage disease (Edwards et al., 2005). The recent
study conducted by Millen and colleagues (2015) suggested there was a joint effect with
vitamin D level and genotypes of known high genetic risk to AMD.
Itty and colleagues (2014) provided information that compared 25hydroxyvitamin D (25OHD) levels in subjects with different forms of AMD
demonstrating lower levels of 25OHD in neovascular AMD (NVAMD), an advanced
form, suggesting vitamin D could be a modifiable risk factor. Kim, Han, and Jee (2014)
conducted a study that concluded that high serum levels of vitamin D were inversely
associated to the advanced form of AMD in men, but not in women. This study differs
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from the one by Parekh and colleagues (2007) in that the latter found serum vitamin D
levels to demonstrate a relationship or association with early AMD, but not in the
advanced form of AMD.
Several studies have evaluated the association between vitamin D levels and
AMD. Of the few studies that have been done, conflicting results have suggested that it is
difficult to draw definitive conclusions based on what is currently known. The
association between vitamin D to AMD still remains unclear and the small number of
studies conducted suggests that this specific association warrants further study.
AMD is a disease of the retina, or back of the eye, that, if left untreated, can lead
to blindness. AMD is classified by four stages: no AMD, early AMD, intermediate AMD,
or late AMD (Van Lookeren Campagne, LeCouter, Yaspan, & Ye, 2014). There are two
types of late stage AMD: NVAMD (often referred to as wet AMD) and geographic
atrophy (GA; often referred to as dry AMD) (Van Lookeren Campagne et al., 2014;
Ferris et al., 2013).
Few recognized phenotypes exist for AMD. AMD fundus photos are imaging
pictures that are taken of the retina (the back part of the eye) in a doctor’s office to
identify and diagnose the disease (Bird et al., 1995). Classification of the photos using
different grading systems can result in patients that demonstrate a phenotype that falls in
a category that is specific to the disease (NEI, n.d.). AMD patients will often demonstrate
similar fundus photo characteristics that can be categorized as having the same phenotype
(NEI, n.d.).

4
Vitamin D (25OHD) is a fat-soluble vitamin that can be found in some foods and
is broken down by ultraviolet light (National Institutes of Health Office of Dietary
Supplements, 2015). Vitamin D has been shown to play multiple roles in human health
including its anti-inflammatory effects and that it is also an immune-modulator (Golan,
Shalev, Treister, Chodick, & Loewenstein, 2011; Manolagas, Provvedini, Murry,
Tsoukas, & Deftos, 1986). Calcitriol is the active hormonal form of vitamin D and has
been demonstrated to affect endothelial cells (Albert et al., 2007). Proteins for the vitamin
D receptor and the enzyme that converts the major circulating metabolites of vitamin D to
its active hormone, calcitriol, are expressed in the retina (Zampatti et al., 2014). Albert
and colleagues (2007) utilized a mouse model to demonstrate that calcitriol was a potent
inhibitor of retinal neovascularization. Their data suggested that calcitriol might provide
benefits in patients with neovascular eye diseases (Albert et al., 2007).
Vitamin D deficiency may increase the risk for developing AMD (Itty et al.,
2014; Parekh et al., 2007). Few studies have examined the association of vitamin D levels
and AMD. Parekh and colleagues (2007) conducted a study using the National Health
and Nutrition Examination Survey (NHANES) data from 1988 through 1994 and found
levels of vitamin D to be inversely associated with early AMD, but not advanced AMD,
suggesting the vitamin may provide a protective role for the disease. Since then, several
studies have shown an association of AMD with vitamin D (Millen et al., 2015; Itty et al.,
2014; Kim et al., 2014;). However, several studies have not found an association
(Cougnard-Gregoire et al., 2015; Park et al., 2014). Study design and data collection
methods could be weaknesses that prevented the detection of an association. For
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example, data collection methods and samples were taken primarily from a Korean
population in the Park and colleagues (2014) study.
Statement of the Problem
Current global estimates indicate that 30–50 million people have AMD (Birch &
Liang, 2007). Those numbers are projected to rise to 288 million by the year 2040
(Wong, 2014). AMD is the leading cause of severe and irreversible vision loss in the
developed world in people older than 50 years and continues to grow as a public health
problem (Wong, 2014). It is critical to continue to attempt to understand factors that
affect the development of the disease or potentially advance disease progression.
Conflicting results from the limited number of studies on the association of vitamin D
and AMD suggest a gap in the literature and justification that further investigation is
warranted. Additional research on the association of vitamin D and AMD may provide
more information that will assist in awareness and understanding of factors related to the
disease. Identifying factors that could be easily modified has the potential to positively
affect the growing public health burden.
Purpose of the Study
The purpose of this study was to examine the association between vitamin D and
AMD. I used a quantitative cross-sectional approach to address this gap in knowledge. I
also used a logistic regression statistical methods analysis to examine data in the
NHANES database that was collected by examiners on vitamin D and identified stages of
AMD level graded from fundus eye exams. The study compared vitamin D levels to
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stages of AMD disease across participants attempting to explore whether an association
existed.
The independent variable in the study was level of vitamin D. The dependent
variable was stage of AMD. The covariates were diabetes, age, race, and smoking status.
Research Questions and Hypotheses
The following research questions and hypotheses have been derived from a
review of existing literature on the topic of vitamin D level and its association with
AMD.
RQ1: What is the association between vitamin D level (high versus low) and the
development of AMD?
H01: There is no association between vitamin D level (high versus low) and the
development of AMD.
Ha1: There is an association between vitamin D level and the development of
AMD.
RQ2: What is the association between diabetes (yes/no) and development of
AMD?
H02: There is no association between diabetes (yes/no) and the development of
AMD.
Ha2: There is an association between diabetes (yes/no) and the development of
AMD.
RQ3: What is the association between age and development of AMD?
H03: There is no association between age and the development of AMD.
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Ha3: There is an association between age and the development of AMD.
RQ4: What is the association between race and the development of AMD?
H04: There is no association between race and the development of AMD.
Ha4: There is an association between race and the development of AMD.
RQ5: What is the association between smoking (yes/no) and the development of
AMD?
H05: There is no association between smoking (yes/no) and the development of
AMD.
Ha5: There is an association between smoking (yes/no) and the development of
AMD.
RQ6: What is the association between vitamin D level and the development of
AMD, after controlling for covariates?
H06: There is no association between vitamin D level and the development of
AMD after controlling for covariates.
Ha6: There is an association between vitamin D level and the development of
AMD after controlling for covariates.
I analyzed the first five questions using binary logistic regression with a binary
outcome AMD (yes = 1 and no = 0). I analyzed the final (sixth) question using a
multivariate model. Logistic regression modeling was used to develop the most
parsimonious model with significant risk factors associated with the development of
AMD.
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Theoretical Framework for the Study
The theoretical base for this study was the life course epidemiology model.
According to Parekh and Zizza (2013), the life course theory when applied in
epidemiology can provide a framework that will examine how nutrition along with other
risk factors can have a long-term effect on chronic disease development. This theory was
utilized to explore how certain risk factors have an association to the disease in question
through time or the in the course of an individual’s life (Parekh & Zizza, 2013). This
theory was utilized to better understand biological, environmental, and psychosocial
pathways and how they collectively affect the natural history of an individual’s health
(Parekh & Zizza, 2013). This approach was utilized to examine the association of vitamin
D and the role it potentially played in development of AMD, which is a disease that
develops through time. I considered only biological and environmental factors in this
study. I provide a more detailed explanation in Chapter 2. In Table 1, I present an
overview of the constructs utilized for this research.
Table 1
Overview of Constructs
Variable

Biological pathway

Vitamin D level

Environmental pathway
X

Diabetes

X

Age

X

Race

X

Smoking status

X

X
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Nature of the Study
Although with conflicting results, several studies have been conducted to better
understand the association between level of vitamin D and AMD disease development
and stage of disease. Therefore, the rationale for this study was to evaluate large numbers
of subjects with the hope to strengthen the results of the data while adding to the existing
literature. The selection of utilizing the existing NHANES database and running a
secondary analysis provided the opportunity to have these large numbers.
The key study variables included vitamin D level; AMD status; and presence of
diabetes, age, race, and smoking status. In this study, I sought to better understand the
association between vitamin D level with the development of AMD, while considering
the covariates of age, race, diabetes, and smoking status.
In my cross-sectional study, I utilized a quantitative methods approach to
implement a logistic regression analysis using an existing dataset. The 2005–2008
NHANES dataset contains serum concentration levels of vitamin D as well as retinal
fundus photographs graded and categorized by AMD severity scale. This 2005–2008
dataset from NHANES was utilized to analyze the association of vitamin D levels to
AMD severity from an available sample size of 5,604 individuals (Centers for Disease
Control and Prevention [CDC], 2015).
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Definitions
Age-related macular degeneration (AMD): A progressive degenerative disease of
the macula – an area of the retina responsible for visual acuity and color vision (Van
Lookeren Campagne et al., 2014).
Early age-related macular degeneration : Generally referred to as dry AMD – is
characterized by medium drusen >63 µm and ≤125 µm with no AMD pigmentary
abnormalities, and generally causes only minimal visual acuity impairment (Van
Lookeren Campagne et al., 2014).
Diabetes: A disease in which an individual’s blood glucose, or blood sugar levels
are too high – typically a fasting plasma glucose higher than 7.0 mmol/l (NIH, 2016).
Fundus imaging eye exams: The process where 2-D or 3-D retinal semitransparent
tissues are projected using reflected light onto an imaging plane (Abramoff, Garvin, &
Sonka, 2010).
Intermediate age-related macular degeneration : Also generally referred to as dry
AMD – is characterized by large druze >125 µm and/or any AMD pigmentary
abnormalities, and generally causes only minimal visual acuity impairment (Van
Lookeren Campagne et al., 2014).
Late age-related macular degeneration : Also referred to as advanced AMD, this
condition has two forms: (a) NVAMD (wet/exudative AMD) and (b) GA (Van Lookeren
Campagne et al., 2014).
Vitamin D: A fat-soluble vitamin naturally occurring in few foods, added to others
and available as a dietary supplement (NIH, 2014).
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Assumptions
I utilized data collected from NHANES. The NHANES database is publicly
available and I assumed that the fundus photos taken have been read and graded
correctly. I also assumed that the correct sampling and testing methods were utilized for
quantitative analysis of vitamin D level. In addition, I assumed that individuals that
participated did so willingly, thereby lessening the chance of bias. These assumptions
were necessary to the validity of the study being conducted.
Scope and Delimitations
The 2005–2008 NHANES database used an oversampling of persons aged 60
years and older (CDC, 2015). This particular aspect of the data was beneficial for the
current study as I sought to better understand the association between variables in a
disease that occurs in the aging population. The nature of the NHANES database
sampling accounted for why it made sense to use this population to run an analysis
looking at better understanding a disease in an aging population. In addition, having the
independent and dependent variables both measured in a manner that minimized recall
bias contributed to the strength of the data outcomes and conclusions.
A drawback was that all of the individuals in this population dataset were from
the United States. It was a large sampling in the NHANES database and was
generalizable to the overall U.S. population. However, utilizing data from only one
country creates a challenge in saying the conclusions are generalizable to populations in
other countries and delimits implications to U.S. populations.
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Limitations
A limitation of the study was the potential for individual participant bias for the
portions of data that were self-reported. Covariates smoking and diabetes were both selfreported by participants. Smokers may contribute bias by providing self-reported answers
they believed were more socially desirable. In addition, medical records indicating
diabetes diagnosis could have been more accurate than participant self-reports. As stated
previously, AMD is a disease of those older than 55 years. Memory recall may be
potentially worse in this age population contributing to recall bias. Other covariates
included age and race; these are both straightforward and should not contribute to bias
that influences outcomes. Fortunately, the manner of data collection for both the
independent variable (vitamin D level) and dependent variable (stage of AMD)
minimized recall bias. Examiners in a lab tested vitamin D level and masked readers did
the reading of retinal images (NHANES, 2015). However, the lab method for vitamin D
measurement changed (discussed further in Chapter 3) from the 2005–2006 and 2007–
2008 data collection years and presents a potential limitation through measurement bias.
Additional measures were not needed to address limitations of the study.
Significance
In the United States, an estimated 1.75 million adults older than 40 years have
some form of advanced AMD (Cheung & Eaton, 2013). By 2020, that number is
expected to climb to approximately 3 million (Wong et al., 2014; Brantley et al., 2012).
AMD is still the leading cause of blindness in the Western world (Brantley et al., 2012).
Globally, AMD is the third leading cause of visual impairment with an estimated
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blindness prevalence of 8.7% (WHO, 2014). Several risk factors have been associated
with AMD including age, race, smoking, a number of genetic risk factors, and diet
(Chew, Clemons, Milton, & Sperduto, 2007; Klein, Peto, Bird, & Vannewkirk, 2004).
The greatest risk for developing AMD is attributed to age, as data suggested that greater
than 15% of white women older than 80 years have advanced forms of AMD (Klein et
al., 2004). AMD has a significant and growing effect on public health and poses
significant economic and social burdens. By demonstrating that there is an association
between vitamin D level and development of AMD, this research may effect positive
social change at a global level. If an association is found and can successfully be
established, AMD disease progression may be addressed with vitamin D
supplementation. If identifying this association can lead to a supplement that lessens
disease progression and AMD patients have better outcomes, then an additional social
implication includes the potential to a reduced burden on the cost of health care.
Summary
AMD is a complicated disease with a growing burden on public health. Several
potential modifiable risk factors warrant further exploration. There is limited research on
the association of serum vitamin D levels with AMD disease progression. This study may
add to the literature on this topic and address this gap in knowledge. If an association
between the two can be more clearly defined, then the study results may have a
meaningful effect on AMD disease progression and mitigating the effects on the growing
future public health burden. If vision can be spared, then patients may have better
outcomes and lead more normal lives.
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In Chapter 2, I review the existing literature on the topic of vitamin D association
to AMD. I also discuss how the existing research serves as a foundation for this study and
a need to learn more. In Chapter 2, I provide a discussion of the literature with a focus on
the findings as well as challenges. I conclude Chapter 2 with how outcomes and
implications from past research have the potential to guide further research and address
existing gaps.
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Chapter 2: Literature Review
Introduction
AMD is a disease of the back of the eye, which can result in blindness if left
untreated. AMD is classified by four stages: no AMD, early AMD, intermediate AMD, or
late AMD, with two types of late stage AMD: neovascular (or wet) AMD and GA (or
dry) AMD (Van Lookeren Campagne et al., 2014; Ferris et al., 2013). It is projected that
the current estimate of 30–50 million individuals living with AMD will grow to 288
million by 2040 (Singer, 2014; Wong, 2014). With this growing prevalence and affect on
the public health system, it will be beneficial to better understand underlying factors that
contribute to AMD disease development that could potentially be modified. The risk for
developing AMD may be increased in the presence of vitamin D deficiency (Itty et al.,
2014; Parekh et al., 2007). A limited number of studies have been done that look at the
association of vitamin D levels and AMD. Vitamin D deficiency is a modifiable risk
factor that is still not fully understood as it pertains to AMD and warrants further
exploration. Several studies have been completed that I explored in detail. These studies
have been largely inconclusive, with conflicting results among them. Some conclude by
suggesting there is a possible association, whereas others indicate that an association
between vitamin D deficiency and AMD development does not exist.
In Chapter 2, I discuss the literature review strategy. In addition, I describe the
theoretical foundation with a rationale for why I chose it and I examine a review of the
current literature related to key variables and concepts. Last, I conclude Chapter 2 with a
summary of major themes in the literature and how this study fills the identified gap.
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Literature Search Strategy
The search strategy included review of publications that reported on AMD,
vitamin D, and vitamin D deficiency by searching the following databases: PubMed,
Academic Search Premier, Science Direct, Google Scholar, and the Walden library. I
searched these databases for relevant papers that were published on this topic until May
2016, which included the following search terms in various combinations: age-related
macular degeneration, vitamin D, vitamin D deficiency, serum vitamin D, risk, AMD
status, or cross-sectional study. This strategy assisted in identifying studies that examined
the association of vitamin D to AMD in different types of studies. It is a relatively new
topic to assess the link between vitamin D level and development of AMD. Therefore, the
search was not limited in terms of how far back I searched for studies, but the relevant
literature included was 10 published papers from 2007 to 2016. The two papers from
2007 were relevant and included because one was the only other NHANES database
review on this topic and the other evaluated the role of calcitriol/vitamin D on retinal
neovascularization in animals precipitating the necessity to understand the effect in
humans (Albert et al., 2007; Parekh et al., 2007). There remains a gap in the literature on
this topic of vitamin D association to AMD despite the list of studies discussed here.
Theoretical Foundation
I introduced the theoretical base for this study in Chapter 1, the life course
epidemiology model. The life course theory studies biological, environmental, and
psychosocial pathways that play a role in an individual’s life span as it relates to
development of chronic disease (Parekh & Zizza, 2013). However, my work focused on

17
the biological and environmental pathways only. The life course approach is a
methodology that provides a framework to analyze how risk factors can affect disease
development in an individual’s life through time. The life course theory was introduced
in the 1960s by connecting several general principles including social change, social
structure, and individual action to guiding the foundation of life course research (Giele &
Elder, 1998).
This life course theory helps explain disease patterns across populations through
time and attempts to better understand if and how exposures effect chronic disease
development. The life course theory may employ either qualitative or quantitative
approaches. Quantitative approaches include the following: life event history analysis,
longitudinal studies, as well as cohort and cross-sectional designs. The current research
utilized a cross-sectional design for data analysis.
Ben-Shlomo and Kuh (2002) discussed propositions, hypotheses, and challenges
of the life course approach to chronic disease epidemiology back when increasing interest
in using this framework began. The life course theory employs an approach that
examined long-term affect of physical and social exposures throughout gestation,
childhood, adolescence, young adulthood, and later life attempting to explore how the
exposures had an effect on chronic disease risk (Ben-Shlomo & Kuh, 2002). There have
been chronic disease cohort studies conducted in the past that implemented the life course
theory by collecting baseline measures, then following patients and analyzed changes in
exposure data based on the follow up metrics collected. A challenge of this type of
analysis that has been observed was that despite baseline measures (including birth
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weight and socioeconomic status) being accounted for, there existed a temporal
relationship between variables that was not considered (Ben-Shlomo & Kuh, 2002).
Considering there are multiple factors or exposures that play a role in disease and
the significance of understanding the timing of the exposures, it should come as no
surprise that disease risk is affected by the exposures in multiple ways (Ben-Shlomo &
Kuh, 2002). The ways the exposures are interrelated should be acknowledged and
considered. For the purposes of this study, a cross-sectional approach was utilized to look
at a snapshot of multiple factors and how they each played a role in development of
disease. Further research can be conducted to look more closely at the temporal
relationship between the variables.
Ben-Shlomo and Kuh (2002) postulated that it is important to understand the
natural history of a biological system, the temporal relationship between exposures and
how across different periods through the life course that the exposures can influence
biological development differently. For example, an exposure earlier in life may not
necessarily have an appreciable effect on an individual’s disease development rate or
health decline in the same way that it might if the same exposure happened later (BenShlomo & Kuh, 2002). Ku and Ben-Shlomo (2004) share an example of how an early life
exposure can reduce lung function potential, but by comparison the mid to later life
exposure accelerates the age-related decline even further. This observation makes a case
for the following assumption: there is a critical period that an exposure can have a lasting
or lifelong effect on a biological system or affect the development of disease (Kuh &
Ben-Shlomo, 2004). It also seems counter intuitive as one might think the earlier
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exposure would send a person on a longer path of decline that started sooner resulting in
a worse outcome through time. If vitamin D level does affect development of AMD
disease or disease progression, it should be considered at what point is it important to
manage vitamin D levels through supplementation that has the greatest chance to reduce
the risk of disease. This could be explored later, but a critical period may exist that
vitamin D level as an exposure for disease poses the greatest risk. If so, it is possible that
the critical period relates to the temporal relationship it plays with the other variables.
The life course epidemiology model makes sense for this research because it
provides a framework for understanding how behavioral changes can affect disease
prevention and may interrupt a disease cycle (Parekh & Zizza, 2013). The current
research attempts to understand if modifying vitamin D levels in deficient individuals can
interrupt the AMD disease cycle by slowing or preventing disease progression and
address this gap in the literature.
Literature Review Related to Key Variables
AMD Risk Factors
The Age-Related Eye Disease Study (AREDS) Research Group ran a large
clinical trial sponsored by the NEI from 1992 through 1998 that enrolled 4,757
participants with varying degrees of AMD severity in an attempt to learn more about and
better understand the clinical course, risk factors, and prognosis of AMD and age-related
cataracts (AREDS, 2005). The primary results at the end of the study in 2001 concluded
that the AREDS vitamin supplement that was studied was successful in slowing or
preventing progression of advanced AMD (AREDS, 2005). The AREDS study has
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resulted in many subsequent papers and analysis to further understand AMD and
confirmed or established various associated risk factors. Among them were the risk
factors of age, race, smoking status, and diabetes that were included in this study as
covariates.
Age. AMD is a progressive disease that can ultimately lead to GA or NVAMD as
individual’s age. AMD prevalence has been demonstrated to be age related in multiple
studies. The AREDS study found increasing age (60 years and older, up to 80 years old)
to be a risk factor for NVAMD and GA (AREDS, 2000). Chew and colleagues (2014)
confirmed age as a risk factor in the subsequent AREDS2 study. The age risk factor
continues to increase as the individual becomes older (Friedman et al., 2004; AREDS,
2000). According to the Chew and colleagues (2014) AREDS report, increasing age
causes risk progression to the advanced form of AMD to go up. A pooled analysis from
three large population-based studies, the Beaver Dam Study, the Rotterdam Study, and
the Blue Mountains Eye Study that included 14,752 participants demonstrated age to be a
risk factor with a clear association across AMD subtypes and all studies (Smith et al.,
2001).
Race. When analyzing race as a risk factor, multiple large population basedstudies have indicated being Caucasian presents the greatest risk (Friedman et al., 2004).
Combining the Beaver Dam Eye Study, the Blue Mountains Eye Study, the Rotterdam
Study, and the AREDS study including 1000’s of participants, all have found being white
versus other races presented the greatest risk in developing AMD (Chew et al., 2014;
Friedman et al., 2004; AREDS, 2000). The Eye Diseases Prevalence Research Group
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reported that more than 1 in 10 Caucasians aged 80 years and older has the advanced
form or neovascular form of AMD (Friedman et al, 2004). Hispanic persons were found
to have the lowest rate of AMD when compared to white and black counterparts
(Friedman et al., 2004). The current study attempted to explore the association of race to
AMD even further.
Smoking. Smoking has been extensively studied and fairly well established as a
risk factor to AMD. The AREDS study found smoking to be a risk factor associated to
the advanced neovascular form of AMD (nAMD) (AREDS, 2000). Chew and colleagues
(2014) also found an association between smoking and AMD disease and found smoking
to be the greatest risk in the oldest group of individuals (age 75 to 80 years old) that were
in the most severe AMD category at baseline. The Blue Mountains Eye Study that
included 3,654 participants, found smoking at the time of baseline exam was associated
with an increased risk of both incident GA as well as the late form of AMD (Wang et al.,
2007; Tomany et al., 2004). Furthermore, it has been found in multiple studies that
current smokers were at higher risk than both past and non-smokers of developing
incident AMD (Chew et al., 2014; Tomany et al., 2004). Tomany and colleagues (2004)
reported that current smokers are 6.19 times more likely and past smokers were 5.52
times more likely to develop NVAMD than their non-smoking counterparts.
A ten-year follow-up of the Blue Mountains Eye Study that included 2,454
participants continued to demonstrate smoking association to AMD (Wang et al., 2007).
Smith and colleagues (2001) reported that smoking was the principal known preventable
exposure associated with any form of AMD based on pooled data from three large studies

22
including 14,752 individuals. This pooled analysis of the Beaver Dam Study, Rotterdam
Study, and Blue Mountains study found tobacco smoking to be the only factor, apart from
age, to demonstrate a clear association to both types of AMD (the neovascular form as
well as GA) across all studies (Smith et al., 2001). At the time this research was
conducted, smoking status presented the most easily modifiable risk factor that can affect
AMD disease incidence and progression.
Diabetes. Diabetes is a major public health issue in the United States and
continues to increase in prevalence. As prevalence increases, so does the demand on
health care facilities through increased amount of disability, loss of productivity, and in
some cases premature mortality (Rahman, Rahman, Ismail, & Rashid, 2007).
Microvascular and macrovascular comorbidities are common in patients with diabetes
(Rahman et al., 2007). Diabetes has been studied as a potential risk factor to association
for development of AMD, a microvascular disease. The AREDS study (2005) found a
weak association of diabetes as a risk factor to AMD based on medical history that
reported the individual was under treatment for diabetes. In addition, the Blue Mountains
Eye Study found having diabetes to be associated with the development of incident GA
(Tomany et al., 2004). Diabetes as a risk factor for AMD still has limited data to support
it. Exploring this risk factor further in the current study had the greatest potential of the
covariates to add to the existing gap in the literature on exploring AMD risk factors. A
better understanding of the association of diabetes to AMD broadens the scope of further
understanding implications of growing incidence of both diabetes and AMD diseases.
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Vitamin D. Using the aforementioned literature research strategy, ten research
papers that include similar constructs of interest and the cross-sectional methodology are
discussed in further detail. Of the ten papers, six studies (spanning from 2007 through
2015) utilized cross-sectional methodology similar to the scope of this study. The other
four studies included: a study conducted by Albert and colleagues (2007) done in
animals, a case series study done by Seddon et al. (2011), a prospective combined
systems analysis by Morrison and colleagues (2011) including a family-based cohort as
well as multiple case control cohorts, and a retrospective longitudinal analysis study done
by Day and colleagues (2012).
Of all the research that has been done on this topic so far, most of the various
researchers have utilized the cross-sectional study design approach, with the exception of
the longitudinal cohort study done by Day et al. (2012), case series by Seddon et al.
(2011), and prospective case control study by Morrison et al. (2011). The cross-sectional
approach allows the researcher to view the association between a variable and a disease at
a single point in time. The researchers that utilized this approach to attempt to better
understand the association between vitamin D level and AMD disease are discussed in
further detail.
Strengths of the cross-sectional study approach on this specific area of study
include: these studies are relatively quick and easy to conduct; the data on selected
variables is only collected once; multiple exposures and outcomes can be measured; the
ability to measure prevalence for all variables being studied; and the importance of
understanding the prevalence for the disease being studied in a specific population. The
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many listed strengths of the cross-sectional approach contributed to the justification and
rationale for use of the cross-sectional study design in the current study. The crosssectional study design in this particular study allowed for data on the selected
independent variable of vitamin D level and covariates of age, race, diabetes, and
smoking status to all be studied from the measurements that were collected for the
NHANES database.
A strength of the retrospective longitudinal cohort study conducted by Day and
colleagues (2012) was that the study design looked at incident cases of AMD, which by
nature of design required vitamin D deficiency to have occurred before AMD. This can
be viewed as a weakness in cross-sectional study designs that assess prevalence and does
not allow assessment of whether deficient vitamin D level or AMD disease occurred first
(Day et al., 2012).
Weaknesses of the cross-sectional approach in this specific area of study included
the following: difficulty in determining, which came first – the outcome or the exposure
variable; it may be difficult to interpret the associations identified; or inability to measure
incidence. Weaknesses in the retrospective cohort study conducted by Day and
colleagues (2012) included: Medicare claims files were utilized for data and this data
does not contain laboratory findings.
Weaknesses of the prospective case control cohorts conducted by Morrison and
colleagues (2011) discussed here included recall bias and sample size. Telephone
interviews were conducted in this particular study collecting various information. One
key variable where recall bias may have influenced outcome data was on the amount of
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sun exposure reported (Morrison et al., 2011). This data affected how vitamin D as a
variable played a role in disease. In addition, the sample size of the advance AMD cases
was very small and only included 10 individuals (Morrison et al., 2011).
Of the pieces of literature mentioned above, there were conflicting findings as it
pertained to association of vitamin D to AMD. Based on these conflicting findings and
limited number of studies conducted thus far, it would be plausible to consider the
existing cross-sectional study attempting to further validate the existing findings. This
study adds to the literature on the topic of association of vitamin D to AMD. The key
variables for this study included vitamin D level, AMD status, and the presence of
diabetes, age, race, and smoking status. With this study, I sought to better understand the
association between vitamin D level with the development of AMD, while considering
the covariates of age, race, diabetes, and smoking status.
Albert and colleagues (2007) set the stage for attempting to better understand the
role vitamin D played in a variety of eye diseases that contained a neovascular
component by examining calcitriol (1,25-hydroxyvitamin D3) in an animal model. A
mouse oxygen-induced ischemic retinopathy (OIR) model was utilized to evaluate the
role of calcitriol (Albert et al., 2007). Results from this mouse model in the study by
Albert et al. (2007) demonstrated that calcitriol-treated animals showed a significant
decrease in retinal neovascularization compared to control. These results suggested a link
of vitamin D level to neovascular driven retinal disease that warranted exploration to
begin in human studies. This particular study contributed to a gap of the association
between vitamin D to AMD that needed further exploration.
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Cross-sectional studies
Parekh and colleagues (2007) conducted the first study to attempt to better
understand the association between vitamin D and AMD. This first study utilized a crosssectional approach to evaluate the third NHANES from 1988 through 1994 (Parekh et al.,
2007). The study was attempting to find additional risk factors and considered vitamin D
because sunlight exposure had been suggested as a potential risk factor (Klein et al.,
2004; Taylor et al., 1992). Parekh and colleagues (2007) explored the association of food
and supplement sources of vitamin D to prevalence of AMD. The final analysis from the
NHANES III utilized a logistic regression to study data from 7752 individuals and found
vitamin D to be inversely associated to early AMD, but did not find the same association
to advanced AMD (Parekh et al., 2007). Parekh and colleagues (2007) study was limited
by having a small number of only 10 individuals in the advanced AMD group. However,
the paper set the stage for justifying further research to confirm these findings. As a
result, six subsequent cross-sectional studies were conducted as follow up in attempt to
better understand the suggested association.
Millen et al. (2011) and Golan et al. (2011) published the subsequent crosssectional studies on this topic and published conflicting results within the same year.
Millen and colleagues (2011) were the second study that demonstrated a relationship by
confirming an association of vitamin D status to development of AMD in Caucasian
postmenopausal women from the Carotenoids in Age-related Eye Disease Study
(CAREDS) population. AMD classification in this study was based on retinal fundus
photographs taken of the 1,313 sample size of individuals from the years of 2001 through
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2004 (Millen et al., 2011). This cross-sectional study model utilized a logistic regression
statistical analysis method to evaluate the association of serum vitamin D concentrations
from multiple sources (dietary, supplement, and sunlight) to prevalence of AMD in a
study population of 1,313 women (Millen et al., 2011).
Millen and colleagues (2011) did not find a protective effect from reported direct
sunlight hours. However, analyses of this postmenopausal sample of women confirmed
the protective effects of vitamin D status to prevalence of AMD, similar to the results
from Parekh and colleagues (2007). A limitation of this study was that the conclusions
could only be extrapolated to Caucasian postmenopausal women. In addition, there was a
potential for recall bias in this study as sunlight exposure since the age of 18 years of age
was self-reported by participants (Millen et al., 2011).
Golan and colleagues (2011) utilized a cross sectional study approach to evaluate
the connection between vitamin D levels and AMD in a study population including
members of the Maccabi Healthcare Services (MHS) aged 60 years or above. The study
population included 9,176 individuals – 1,045 with AMD and 8,124 non-AMD subjects
(Golan et al., 2011). Golan et al. (2011) expected to find that AMD patients would have
lower levels of vitamin D compared to their non-AMD counterparts, but instead they
found higher levels of vitamin D were not associated with lower prevalence of AMD.
Potential limitations of this study included: food and supplement intake of individuals
was not accounted for; nor was the amount of sun exposure (Golan et al., 2011). A
strength of this study was the relatively large number of AMD individuals included in the
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study, which made it unlikely that the negative results were a result of a type II error
(Golan et al., 2011).
Two large cross-sectional epidemiology studies investigating the association of
vitamin D with AMD were conducted in 2014; one by Kim et al. (2014) and another by
Itty and colleagues (2014). The three large epidemiologic studies prior generated
conflicting results (Parekh et al., 2007; Millen et al., 2011; Golan et al., 2011). The study
by Itty et al. (2014) concluded with similar findings to Parekh and colleagues (2007) and
Millen et al. (2011). Whereas Kim et al. (2014) concluded with conflicting results
suggesting there was an inverse association between high levels vitamin D and late AMD
in men, but not in women.
Kim et al. (2014) evaluated a large sample of 17,045 individuals from the Korean
National Health and Nutrition Examination Survey (KHANES) from 2008 to 2012. This
study defined AMD in two categories, early and late. Early AMD was defined by
presence and type of drusen, whereas late AMD was defined by the presence of wet
(nAMD) or dry AMD (GA) (Kim et al., 2014). Simple and multiple logistic regression
statistical methods were utilized in this study and results found the prevalence of late
AMD was inversely associated with high vitamin levels in men but not in women (Kim et
al., 2014). There was not a correlation found for early AMD in either men or women
(Kim et al., 2014).
A strength of the study by Kim et al. (2014) was the large sample size. However,
there were several limitations that included: inability to adjust for seasonal variation in
vitamin D level, difficulty inferring causality based on study design type, capturing of
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data on individuals that had their wet AMD treated with antivascular growth factors, and
last the lack of detailed data on sunlight exposure (Kim et al., 2014). Sunlight exposure
may be variable throughout the year and was not accounted for in this study, but it is
questionable if the Asian population demonstrated seasonal variation in vitamin D status
(Kim et al., 2014).
Itty and colleagues (2014) sought to explore the association of vitamin D
deficiency to NVAMD and nonneovascular AMD (NNVAMD) compared to matched
controls from a Duke University Medical Center population (aged 55 years and older)
from July 1997 through November 2011. A total of 462 participants whose vitamin D
levels had been measured were included in the study: 146 with NVAMD, 216 with
NNVAMD, and 100 matched controls (Itty et al., 2014). This study done by Itty et al.
(2014) found higher rates of vitamin D deficiency in the NVAMD group compared to
those in the NNVAMD group and matched controls. There were limitations to this study,
including the lack of temporal connection that goes along with a retrospective review.
These findings were consistent with some of the previous studies mentioned and justify
further review.
Cougnard-Gregoire and colleagues (2015) conducted the most recent crosssectional population based study to explore the association between vitamin D deficiency
and AMD. The study included 697 individuals from an elderly population (aged 72.7 +
4.4 years) in Bordeaux France (Cougnard-Gregoire et al., 2015). Methods included
collection of plasma vitamin D concentrations collected from 1999–2001 compared to
retinal photographs with images classified as early or late AMD (Cougnard-Gregoire et
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al., 2015). Early AMD was defined by drusen whereas late AMD was defined by
NVAMD or GA (Cougnard-Gregoire et al., 2015). The study found prevalence of
vitamin D deficiency to be very high at 83.2%, yet no associations of vitamin D status
were found with any stage of AMD (Cougnard-Gregoire et al., 2015).
A limitation of the study by Cougnard-Gregoire and colleagues (2015) was the
small number. However, there were several strengths including: objective measurement
of vitamin D, blood samples taken at different times of the year, and confounders such as
BMI, sociodemographic status, use of certain medications, factors related to vascular
diseases, relevant genetic polymorphisms (Cougnard-Gregoire et al., 2015). The results
reported in the Cougnard-Gregoire et al. (2015) study that did not support a role of
vitamin D to AMD were similar to what Day et al. (2012) found as well as Golan et al.
(2011). The existing evidence of an association between vitamin D level and AMD status
were inconsistent and warranted further study.
Longitudinal Cohort Study
Day and colleagues (2012) conducted a retrospective longitudinal cohort study in
Medicare beneficiaries examining a possible association between vitamin D deficiency
and subsequent AMD diagnosis (of either the neovascular or non-neovascular form).
Medicare 5% claims files from 2004 through 2006 were utilized to identify a patient
population of 6,966 individuals with vitamin D deficiency (Day et al., 2012). Individuals
with an AMD diagnosis that preceded the vitamin D deficiency diagnosis were excluded
(Day et al., 2012). Results from this study did not find an association of vitamin D
deficiency to diagnosis of either form (neovascular or non-neovascular) of AMD to be
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statistically significant (Day et al., 2012). Although the findings of Day et al. (2012) of
no association of vitamin D levels to AMD were similar to those of Golan and colleagues
(2011), they were contrary to what several previous studies had shown.
A strength of the study by Day and colleagues (2012) was the design looked at
incident cases and therefore differed from the other studies mentioned because in this
study it was known that vitamin D deficiency occurred first (Day et al., 2012). This was
the first study to examine incident cases rather than prevalence of AMD disease (Day et
al., 2012). A weakness of this study was lack of laboratory results from the type of claims
data utilized (Day et al, 2012).
Case Series Study
Seddon and colleagues (2011) conducted a case series study to evaluate the affect
of behavioral and nutritional factors (including vitamin D dietary intake) on AMD in
Caucasian male monozygotic twins. Fundus photographs that were graded by Wisconsin
Grading System were utilized to evaluate stage of disease (Seddon et al., 2011). The
Wilcoxon signed-rank test and linear regression statistical models were utilized to assess
the associations between the various nutritional and behavioral characteristics (including
vitamin D level) and stage of AMD disease (Seddon et al., 2011). The results of this
study found dietary intake of vitamin D to be inversely associated with AMD, drusen
size, and drusen area (Seddon et al., 2011). Although they explored different population
types, the results of this case series by Seddon et al. (2011) along with those of the crosssectional study conducted in the same year by Millen and colleagues (2011) both
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supplemented the original findings by Parekh and colleagues (2007) that suggested there
was an association between vitamin D level and AMD disease status.
Prospective Cohort Studies
Morrison and colleagues (2011) utilized a family based cohort study of 50 sibling
pairs to examine vitamin D levels compared to AMD. Data on vitamin supplementation
was collected via questionnaire and UV exposure was based on location of where
individuals lived for the majority of their lives (Morrison et al., 2011). Limitations of this
type of data collection included recall bias as it pertains to vitamin D supplementation
and quantification of sunlight exposure is difficult to assess at best. Results from this
study suggested a trend toward lower levels of vitamin D in the siblings with NVAMD
compared to higher concentrations of vitamin D in the unaffected counterparts (Morrison
et al., 2014). However, the difference was not statistically significant. This study done by
Morrison et al. (2014) was the first to detect a genetic association between vitamin status
and AMD and is discussed further in Chapter 5.
The limited number of studies discussed above on the topic of vitamin D
association to AMD generated inconsistent findings and suggested further exploration
was needed. There remains a gap in the literature on this topic and more research on the
association of vitamin D status to AMD needs to be done.
Summary and Conclusions
The themes in the literature on this topic to date suggest data is inconclusive.
Most of the studies that have been done exploring the topic of the association of vitamin
D to AMD status were cross-sectional design studies. What is known is that vitamin D
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levels have been shown to be protective in a variety of different conditions (Morrison et
al., 2011). What is not known is how exactly vitamin D plays a role in prevalence of
AMD disease. The limited number of studies on this topic in recent years has found
conflicting results and suggests that more research needs to be done. The present study
explored in a large sample size the association of vitamin D to AMD status and adds to
the existing literature. Using the NHANES database, the association between vitamin D
level and AMD progression was investigated here.
In Chapter 3, I discuss the research design and rationale for this study. I review
the methodology, including: the population, sampling, recruitment, participation, data
collection, and instrumentation. I conclude Chapter 3 with threats to validity and explore
possible ethical concerns or issues.
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Chapter 3: Research Method
Introduction
AMD is a progressive disease that can ultimately lead to one of two forms of the
disease: GA or NVAMD. The most common type of AMD is the nonneovascular form
(dry) or GA. The neovascular, or wet, form of AMD is the leading cause of blindness in
older adults affecting an estimated 1.6 million adults older than age 50 years in the
United States (Melnikova, 2005). Approximately 200,000 new cases of the neovascular
form of AMD are diagnosed in the United States each year (Melnikova, 2005). Limited
data supports the suggestion of a possible association between vitamin D status and
AMD. The purpose of this study was to evaluate the association between vitamin D and
AMD further.
Currently, it is not clear whether there is an association between vitamin D
deficiency and AMD. There is limited data on this topic with conflicting results. The
findings from this study may support the importance of monitoring and maintaining
healthy vitamin D levels. This particular cross-sectional study design using NHANES
data from 2005–2008 used a large population based data sample and tested the five
hypotheses listed in Chapter 1. The first of these hypotheses attempted to understand the
association between vitamin D level (high versus low) and the development of AMD.
The subsequent four hypotheses explored the association of diabetes, age, race, and
smoking status to AMD.
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In Chapter 3, I discuss the research method. In addition, I describe the
instrumentation along with threats to validity and ethical procedures. I conclude Chapter
3 with a summary of the study design and methodology.
Research Design and Rationale
In this cross-sectional analysis, I utilized the NHANES data from 2005–2008 to
test the association between independent variable vitamin D and dependent variable
AMD as well as covariates age, race, smoking status, and diabetes. This research design
was similar to some of the other research studies on this topic. The cross-sectional
research design provides several advantages for this type of study including: crosssectional studies are relatively quick and easy to conduct; the data on selected variables is
only collected once; multiple exposures and outcomes can be measured; the ability to
measure prevalence for all variables being studied; and the importance of understanding
the prevalence for the disease being studied in a specific population (Giele & Elder,
1998). The many listed strengths of the cross-sectional approach contribute to the
justification and rationale for use of the cross-sectional study design in the current study.
In this particular study, the cross-sectional study design allowed for data on the selected
independent variable of vitamin D level and covariates of age, race, diabetes, and
smoking status to all be studied from the measurements that were collected in the 2005–
2006 and 2007–2008 NHANES database.
In my study, I examined a specific point in time to assess the relationship between
the independent variable vitamin D and the outcome variable AMD, as well as the
associations to each of the covariates age, race, diabetes, and smoking status. This
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snapshot in time represented the current status of the disease AMD and the tested factors
in a large nationally representative sample of the population. The results from this
analysis are generalizable to the greater population as to whether associations were
present between the tested variables. Data from this study were extracted from the
NHANES database according to the variables listed in Tables 3 through 6. The total
sample sizes for NHANES 2005–2006 and 2007-2008 were 9,950 and 9,762, respectively
(CDC, 2015b). AMD is a disease that is most likely to occur after the age of 60 years, but
the disease can occur at a younger age. Therefore, I restricted the age cutoff for the 5,604
sample size to adults aged 40 years and older because AMD is a disease of the aging
population and prevalence increases with age. In this cross-sectional study, I utilized the
NHANES database seeking to understand the association between vitamin D and AMD
including covariates age, race, diabetes, and smoking status addresses an important gap in
the literature.
NHANES Dataset
NHANES is a program that began in the early 1960s designed to assess and study
the health of children and adults in the United States (CDC, 2015a). NHANES is a
program of the National Center for Health Statistics (NCHS), which is a part of the
Centers for Disease Control and Prevention (CDC).
The NHANES population is a nationally representative sample across the United
States taken of about 5,000 individuals each year (CDC, 2015a). NHANES over-samples
individuals aged 60 years and older, African Americans, and Hispanics in order to
produce statistics that most closely match the U.S population (CDC, 2015a). The
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interview of this population included socioeconomic, demographic, dietary, and healthrelated questions (CDC, 2015a). The examination portion was carried out by highly
trained medical professionals and included medical, dental, physiological measurements,
and laboratory tests (CDC, 2015a).
Data Collection
NHANES survey data was collected from conducting interviews, physical
examinations, and drawing samples for laboratory testing (CDC, 2013). Interviews took
place in respondents’ homes and health measurements were performed in mobile centers
that were equipped to travel throughout the country (CDC, 2015a). The interviews
collected person-level demographic, health, and nutrition information, in addition to
information about the household (CDC, 2013). The examination included collecting
physical measurements, a dental examination, and the collection of blood and urine
samples for laboratory testing (CDC, 2013).
The study team (many of whom were bilingual in English and Spanish) that
conducted these assessments and collected the information and data included a physician,
dietary and health interviewers, and medical and health technicians (CDC, 2015a).
Advanced computer systems made it possible for interviewers to use notebook computers
and electronic pens to collect information on site. The information was then transmitted
to the NHANES database through devices that included digital scales and stadiometers
(CDC, 2015a). To ensure privacy, respondents were able to enter sensitive information
using touch-sensitive computer screens (CDC, 2015a).
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To encourage participation, the local media was allowed to share information
about the survey. In addition, transportation was provided to and from the mobile center
if needed by the participants (CDC, 2015a). The data collected from respondents was
available to the NCHS staff within 24 hours, expediting the ability to share results with
the public. NHANES data is provided to the public at no charge.
Sampling and Sampling Procedures
The type of sampling methodology changed from NHANES 2005–2006 and
2007–2008 years. All Hispanics (not just Mexican-Americans) were oversampled in the
2007–2008 dataset. The sampling frame for NHANES included all ages of the
noninstitutionalized civilian population of the United States (CDC, 2013). Predesignated
domains of sex-age groups for black persons, Mexican-American persons, and incomesex-age groups for other persons were utilized for oversampling in 2005-2006 (CDC,
2013). Predesignated domains of sex-age groups for non-Hispanic black persons,
Hispanic persons, and income-sex-age groups for other persons were utilized for
oversampling in 2007–2008 (CDC, 2013).
The sample size from 2005–2006 and 2007–2008 included 10,348 and 10,149
individuals respectively. There were 7,081 individuals in the 2005–2008 combined
dataset that were 40 years and older (Klein et al., 2011). Of those, there was a final
sample total of 5,604 individuals from NHANES 2005–2008 of which there were
gradable fundus photographs that have been included for the AMD analysis purposes of
this current study. This final sample of 5,604 participants included 3,017 non-Hispanic
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white individuals, 401 other Hispanic individuals, 1,139 non-Hispanic black individuals,
864 Mexican American individuals, and 183 individuals of other races/ethnicities.
G*Power 3.1 statistical software was utilized to run a power analysis and
compute the required sample size for this study. A priori is the ideal type of power
analysis and is done before a study takes place (Mayr, Erdfleder, Buchner, & Faul, 2011).
An a priori power analysis was conducted using a two-tailed z test for linear regression
with an alpha of 0.05 for statistical significance, a power of 90%, and an odds ratio of
1.2, which powered it to detect a weak association. According to Monson (1990) an odds
ratio below 1.2 is not powered to indicate an association. The probability utilized for this
power analysis was 0.065 because the prevalence or probability of having any AMD in
the United States based on the 2005–2008 NHANES survey data was 6.5% (Klein et al.,
2011). Based on the power analysis conducted using G*Power statistical software, the
minimum sample needed to detect a difference was 5,156. The entire sample size
available of 5,604 was utilized. Evaluation of the association of vitamin D to AMD using
this sample contributed to understanding if there was an association and adds to the
literature on this topic.
Study Variables
Dependent Variable: AMD
In the 2005–2006 and 2007–2008 datasets, AMD was determined by information
on the 3-level severity classification (no ARM, early ARM, or late ARM) of AMD from
the worse eye (CDC, 2015b). Digital images using a Canon CR6-45NM Opthalmic
Digital Imaging System and Canon EOS 10D digital camera were captured from all
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participants aged 40 years and older (CDC, 2005). Fundus photo images were read twice
by an experienced reader using a modification of the Wisconsin Age-Related
Maculopathy Grading Sytem (CDC, 2005). Early ARM was defined by presence or
absence of drusen and/or pigmentray abnormalities (CDC, 2015b). Late ARM was
defined by exudative ARM signs and/or GA (CDC, 2015b). In order to run a binary
logistic regression statistical analysis, ARM codes for 1 = early ARM and 2 = late ARM
were combined and any AMD was defined as early and late AMD. For the purposes of
this study, the eye with the worst severity of lesion was utilized.
Independent Variable: Vitamin D
In the 2005–2006 and 2007–2008 datasets, vitamin D level was determined from
analysis of a serum sample that was collected from participants at a mobile examination
center (MEC) (CDC, 2015b). The staff members were observed for equipment operation,
specimen collection and preparation, and testing procedures (CDC, 2015b). In the 2005–
2006 dataset, the diasorin 25OHD assay method was utilized to determine vitamin D
levels from the individual’s serum (CDC, 2015b). In the 2007–2008 dataset, the vitamin
D lab method changed and utilized an ultra-high performance liquid chromatographytandem mass spectrometric method to calculate a total 25OHD that was the sum of
measured 25-hydroxyvitmain D2 (25OHD2) and 25-hydroxyvitamin D3 (25OHD3)
(CDC, 2015b).
Covariates
Covariates for this study included age, race, smoking status, and diabetes;
participants age 40 years and older were included, self-reported race, self-reported
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smoking status based on how they answered if they had ever smoked a cigarette or
smoked at least 100 cigarettes in life, and if they had ever been told by a physician that
they have diabetes.
Variables: Coding and Questions
This section outlines the NHANES dataset questions and coding that was utilized.
I collected the data from the NHANES 2005–2006 and 2007–2008 datasets.
Demographic data. Demographic covariates age and race were part of the
NHANES datafile ‘Demographic Variables and Sample Weights’ Doc file DEMO_E.xpt
that were collected at the time of screening interview for both data years 2005–2006 and
2007–2008. Age was recorded in years at the time of screening interview. In the 2005–
2006 dataset, responses of age 85 years and older were all coded as 85. In the 2007–2008
dataset, responses of age 80 years and older were all coded as 80. Race/ethnicity were
coded from responses given to the survey questions. These are presented in Table 2.
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Table 2
Baseline Characteristics: 2005–2006 and 2007–2008
Variable name

Description and coding

Variable
type

Study code

RIDAGEYR

Age at screening
Adjudicated - recode

Categorical

0 to 79, 80 (2007–2008)

RIDAGEYR

Age at screening
Adjudicated - recode

Categorical

0 to 84, 85 (2005–2006)

RIDRETH1

Race/ethnicity recode

Categorical

Mexican American,
Other Hispanic, NonHispanic White, NonHispanic Black, Other
Race – Including MultiRacial

Laboratory Data. The independent vitamin D variable data was obtained from
the NHANES datafile VID_D_Doc (2005–2006) and VID_E_Doc (2007–2008). The
vitamin D lab method from 2005–2006 measured total 25-hydroxyvitamin D. The
vitamin D method changed for 2007–2008 and the total 25OHD was the sum of 25hydroxyvitamin D2 and 25-hydroxyvitamin D3. These are presented in Table 3.
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Table 3
Vitamin D
Variable name

Description and coding

Variable type

Study code

LBDVIDMS

Vitamin D (nmol/L)

Binary

High versus low

LBXVIDMS

250HD2+250HD3

Binary

High versus low

Questionnaire Data. Covariate smoking was self-reported by participants as a part of
NHANES Doc file SMQ_D_Doc (2005–2006) and SMQ_E_Doc (2007–2008). The data
collected for the variable utilized in the current study was based on if the participant was
a current smoker or past smoker at the time of questionnaire. Covariate diabetes was a
part of Doc file DIQ_D_Doc (2005–2006) and DIQ_E_Doc (2007–2008). The diabetes
status was self-reported by participants as to whether they had ever been told by a
physician that they had diabetes. The question was answered before the physical
examination. I present these in Table 4.
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Table 4
Covariate: Smoking and Diabetes
Variable name

Description and
coding

Variable type

Study code

SMQ040

Do you now smoke
cigarettes

Binary

Yes (Every day, Some
days) or No (Not at
all)

SMQ020

Smoked at least 100
cigarettes in life

Binary

Yes, No

DIQ010

Doctor told you have
diabetes (both males
and females 1 year –
150 years). Will limit
to age 40–100 years

Binary

Yes, No

Examination Data. The AMD severity determination variable provided
information on the 3-level severity classification of AMD regarding the worse eye. Early
ARM was defined by presence or absence of drusen and/or pigmentary abnormalities.
Late ARM was defined by signs of exudative ARM and/or GA. For any ARM, codes for
1 = early ARM and 2 = late ARM were combined. These are presented in Table 5.
Table 5
AMD Severity Determination: 2005-2006 and 2007-2008
Variable name Description and coding

Variable type

Study code

OPDUARM

Categorical

No ARM, early, late,
missing

ARM, 3 severity levels,
worse eye
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The NHANES dataset categorized the AMD variables as early, late, and none.
Fundus photos taken from participants that have been read by experienced Wisconsin
grading center photographer were utilized to determine AMD status. Similar methods
have been utilized in other epidemiological studies (the AREDS study for example) to
diagnose disease with fundus photography that was more closely similar to clinical exam.
The existing NHANES database utilized for this study relied on fundus photos to
determine AMD status. This was an appropriate way and more accurate way to assess
AMD status than patient recall. This eliminated the possibility of including participants
that had not yet been diagnosed and were not aware that they had early stage AMD
disease.
Methodology
Instrumentation
The data collection instrument I utilized for this dissertation was the NHANES
existing secondary dataset. NHANES data comprised three levels of data from a
representative sample of the U.S. noninstitutionalized civilian population: a household
screener, an interview, and a physical examination (CDC, 2013). When combining 2-year
survey cycles it is important to combine the cycles using the appropriate weights (CDC,
2013b). Therefore, I utilized the 4-year examination weights generated from the MEC
examination for comparisons. I discussed the data analysis of how the four consecutive
years 2005–2008 were weighted in the data collection sampling section.
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NHANES data is available for public use and therefore permission to use the data
was not necessary. The Walden University Institutional Review Board (IRB) approved
this study before being conducted (IRB approval number 10–28–16–0229912). The
validity and reliability of the NHANES database was evaluated in a comparative analysis
across three national health surveys that also included the Behavioral Risk Factor
Surveillance System (BRFSS) and the National Health Interview Survey (NHIS) (Li et al,
2012). According to Li and colleagues (2012), the results of their study supported the
external validity and reliability of all three national health surveys (including NHANES)
and were consistent with previous findings.
Data Analysis Plan
I utilized the IBM SPSS Statistics software package to run the statistical analysis
for this study (IBM Marketplace, n.d.). I utilized a bivariate logistic regression to explore
the association of vitamin D to AMD. The association of AMD to age, race/ethnicity,
smoking status, and diabetes were explored individually and those found to be significant
were included in further analysis using a multivariate logistic regression. Calculations
included descriptive statistics on the tested association between vitamin D and AMD
including the covariates.
Hypothesis 1: There is an association between vitamin D level (high versus low)
and the development of AMD. This variable data was created from blood draw samples
that were taken from participants. I ran a binary logistic regression analysis between
vitamin D level and AMD to test this hypothesis. For this statistical analysis, AMD codes
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for 1 = early AMD and 2 = late AMD were combined to make this a binary logistic
regression analysis.
Hypothesis 2: There is an association between diabetes and the development of
AMD. This variable data was created from participant responses to the question if they
have ever had a “doctor told you have diabetes”. Responses included were yes, no,
borderline, refused, and don’t know. I ran a binary logistic regression analysis between
diabetes and AMD to test this hypothesis.
Hypothesis 3: There is an association between age and the development of AMD.
The participant in response to the survey question reported age at time of screening. The
age cutoff for the sample was restricted to adults aged 40 years and older because AMD
is a disease of the aging population and prevalence increases with age. I ran a binary
logistic regression analysis between age and AMD to test this hypothesis.
Hypothesis 4: There is an association between race and the development of AMD.
I ran a binary logistic regression analysis between race and AMD to test this hypothesis.
This variable data was created from participant self-reported race responses to the survey
questions on race and Hispanic origin. Responses included were Mexican American,
other Hispanic, non-Hispanic White, non-Hispanic Black, and other race – including
multi-racial.
Hypothesis 5: There is an association between smoking and the development of
AMD. The variable data was created from participant’s responses to the survey questions
‘do you now smoke cigarettes’ and have you ‘smoked at least 100 cigarettes in life’. The
following responses to select from in response to ‘do you now smoke cigarettes’ were
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provided - every day, some days, not at all, don’t know, or refuse to answer. The
following responses to select from in response to have you ‘smoked at least 100
cigarettes in life’ were provided – yes, no, or refuse to answer. I ran a binary logistic
regression analysis between smoking and AMD to test this hypothesis. For this statistical
analysis, answers to the smoking questions were re-coded for 0 = Non-Smoker, 1 = Past
Smoker, and 2 = Current Smoker. I utilized these answers for analysis in this binary
logistic regression to test the association between current smoking, past smoking, and no
smoking to likelihood of having AMD.
Hypothesis 6: There is an association between vitamin D level and the
development of AMD after controlling for covariates. I ran a multivariate logistic
regression analysis between all covariates and AMD to examine whether the combined
variables predicted AMD and test this hypothesis.
Threats to Validity
There are a number of strengths to this study, including that the study utilized a
nationally represented large population based sample size including multiple
race/ethnicities. It is also important to consider limitations to internal and external
validity of this study using the NHANES dataset. The institutionalized population was
not included in the sample. Fundus photographs were not able to be collected for all
participants for one reason or another. This should be taken into consideration when
making generalizations to the entire U.S. population. I assume that the vitamin D
instrument utilized to measure serum levels was conducted correctly and has not affected
interpretation of results. Recall bias in this aging population has the potential to affect the
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validity of results. Self-reported data as it pertains to smoking status as well as diabetes
diagnosis needs to be considered. All of these factors should be taken into account when
making assessments based on the results of this study.
Ethical Considerations
The NHANES data is free to be utilized by the public. Individuals that
participated in the NHANES survey received compensation and a report of medical
findings (CDC, 2015a). All of the survey information collected was de-identified and
kept strictly confidential (CDC, 2015a). Participant’s privacy was protected by public
laws (CDC, 2015a). There were no ethical concerns related to participant recruitment,
materials or methods utilized to draw samples, or collection of data for the 2005–2006
and 2007–2008 NHANES dataset utilized for this dissertation.
Summary
I applied the cross-sectional approach to this quantitative study analyzing the
association between vitamin D and AMD using the NHANES data from 2005–2006 and
2007–2008. I included additional research areas of the confounding variables of age,
race, smoking status, and diabetes for analysis. In Chapter 4, I present results of the
analysis I utilized to test the six hypotheses for this study. In it, I discuss data collection
issues and the results of the study.
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Chapter 4: Results
Introduction
The purpose of this study was to examine the association between vitamin D and
AMD. AMD is a destructive eye disorder. Loss of vision translates into an effect on the
emotional aspects of life, puts individuals at risk for falls, and prevents them from
interacting with their families. Many dimensions of this study make it important. The
research questions and corresponding hypotheses were the following:
RQ1: What is the association between vitamin D level (high versus low) and the
development of AMD?
H01: There is no association between vitamin D level (high versus low) and the
development of AMD.
Ha 1: There is an association between vitamin D level and the development of
AMD.
RQ2: What is the association between diabetes (yes/no) and development of
AMD?
H02: There is no association between diabetes (yes/no) and the development of
AMD.
Ha 2: There is an association between diabetes (yes/no) and the development of
AMD.
RQ3: What is the association between age and development of AMD?
H03: There is no association between age and the development of AMD.
Ha 3: There is an association between age and the development of AMD.
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RQ4: What is the association between race and the development of AMD?
H04: There is no association between race and the development of AMD.
Ha 4: There is an association between race and the development of AMD.
RQ5: What is the association between smoking (yes/no) and the development of
AMD?
H05: There is no association between smoking (yes/no) and the development of
AMD.
Ha 5: There is an association between smoking (yes/no) and the development of
AMD.
RQ6: What is the association between vitamin D level and the development of
AMD, after controlling for covariates?
H06: There is no association between vitamin D level and the development of
AMD after controlling for covariates.
Ha 6: There is an association between vitamin D level and the development of
AMD after controlling for covariates.
In Chapter 4, I discuss the data collection and I present the descriptive statistics
for independent, dependent, and potentially confounding variables. I provide the results
of my analysis of the six research questions. Chapter 4 concludes with a summary and
transition to Chapter 5.
Data Collection
This study utilized data collected from the 2005–2008 NHANES database. The
NHANES program began in the 1960s and is a series of surveys designed to assess the
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health and nutrition of adults and children in the United States. It is a nationally
representative sample across the United States taken of about 5,000 individuals each year
(CDC, 2013). NHANES survey data was collected from conducting interviews, physical
examinations, and drawing samples for laboratory testing (CDC, 2013).
I downloaded and coded the NHANES dataset per the aforementioned categories
for analysis with SPSS software. The data was weighted with the NHANES sample strata
and cluster weights as well as full sample 2-year interview (WTINT2YR) and MEC exam
(WTMEC2YR) weights according to the NHANES least common denominator method
(CDC, 2015c; CDC, 2015d). The sample weights were utilized to aid in obtaining an
unbiased estimate of the population because the sample participants were chosen with
unequal probabilities. The strata and cluster statements name the variables that form
strata and identified clusters in the cluster sample NHANES design.
Results
A sample of 10,348 and 10,149 individuals were interviewed in the NHANES
years 2005–2006 and 2007–2008 samples, respectively. From the total, 2,413 and 3,191
individuals in 2005–2006 and 2007–2008 respectively had gradable fundus photos (CDC,
2015c). This allowed me to use a combined total sample of 5,604 individuals with
gradable fundus photos categorized into ARM status for this analysis. Within this 5,604
partial study sample, there were reported results from all 5,604 individuals on age,
diabetes status, and race/ethnicity. There were 5,036 individuals in the study sample with
reported values of vitamin D and 5,602 individuals with reported smoking status. Table 6
provides a further breakdown of the descriptive statistics of each variable by category. In
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table 6, I present the frequencies and percentages for the categorical variables of the
study sample, NHANES sample, and percentages by the weighted population sample.
Table 6
Respondent Sociodemographic characteristics: Study Sample, NHANES Sample, and
Weighted Sample to Represent Population
Study Sample n = 5604*

Frequency

NHANES Sample N =
20,497
%

Frequency

Weighted
Sample

%

%

ARM
Yes

443

7.9

NA

NA

7.9

No

5163

92.1

NA

NA

92.1

1-9.99
10-19.99
20-29.99
30+

177
1590
2049
1220

3.2
28.4
36.6
21.8

534
4748
6414
3550

2.6
23.2
31.3
17.3

2.0
25.0
43.0
30.0

Yes
No

831
4773

15.2
85.2

1298
18,190

6.3
88.7

10.6
89.4

40-59
60+

2829
2775

50.5
49.5

3357
3724

16.4
18.2

64.4
35.6

Vitamin D

Diabetes

Age

Race/Ethnicity
Non-Hispanic White
Other Hispanic
Mexican American
Non-Hispanic Black
Other race

3017
401
864
1139
183

53.8
7.2
15.4
20.3
3.3

8043
1550
5004
4921
979

39.2
7.6
24.4
24.0
4.8

2408
2741
5752

11.7
13.4
28.1

77.1
3.2
5.4
9.6
4.7

Smoking status
Current smoker
Past smoker
Non-smoker

1154
1731
2717

20.6
30.9
48.5

*Number of individuals with gradable fundus photography

20.3
31.2
48.5
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Results for Research Question 1
To answer research question 1, “What is the association between vitamin D level
(high versus low) and the development of AMD?”, I utilized binary logistic regression
using complex samples for vitamin D level and AMD that were extracted from the
NHANES database. The study population was n = 5,036. The NHANES dataset reported
vitamin D levels on only 5,036 individuals from the 5,604 study sample. Vitamin D level
data was missing or unreported for 568 individuals. Table 7 contains the results from the
binary logistic regression.
Table 7
Individual Logistic Regression Results for Variables Vitamin D: Association with
Dichotomous Age-related Macular Degeneration
Characteristic

p

Odds Ratio

95% Confidence Interval
Lower

Vitamin D (ng/ml)
1-9.99 vs. 20-29.99
10-19.99 vs. 20-29.99
≥30 vs. 20-29.99

Upper

.279
.409
.858
1.001

.209
.631
.758

.801
1.168
1.323

The p value of the results of the analysis of the association between vitamin D
level and AMD were found to be .279. The results in the highest levels of vitamin D (30+
ng/ml) had an odds ratio of 1.001 (95% CI: .758 to 1.323) when compared to 20-29.99
ng/ml. The odds ratio for individuals with vitamin D level 10-19.99 ng/ml was .858 (95%
CI: .631 to 1.168) when compared to individuals with 20-29.99 ng/ml. The odds ratio in
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the lowest level of vitamin D (1-9.99 ng/ml) was .409 (95% CI: .209 to .801) when
compared to 20-29.99 ng/ml. These results suggested that overall; vitamin D level was
not associated with AMD. I did not find a vitamin D level association to AMD to be
statistically significant in response to research question 1. However, the only comparison
where the confidence interval does not cross 1 was in the lowest level (1-9.99 ng/ml)
suggesting that there may be a protective association in the lowest level of vitamin D
category when compared to individuals with 20-29.99 ng/ml in this sample. Vitamin D
was the main focus of this analysis; therefore I included it in the multivariate logistic
regression model for research question 6. I failed to reject the null hypothesis for research
question 1 (there is no association between vitamin D level (high versus low) and the
development of AMD) based on the results found for the binary analysis in this study.
Results for Research Question 2
To answer research question 2, “What is the association between diabetes (yes/no)
and development of AMD?”, I utilized binary logistic regression using complex samples
for diabetes status and AMD that were extracted from the NHANES database. The study
population was 5,604. The NHANES dataset reported diabetes status on the entire study
sample of 5,604 with graded fundus photography. Table 8 contains the results from the
binary logistic regression.
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Table 8
Individual Binary Logistic Regression Results for Variable Diabetes: Association with
Dichotomous Age-related Macular Degeneration
Characteristic
Diabetes
Yes vs. no

p
.272

Odds Ratio
1.258

95% Confidence Interval
Lower
Upper
.952

1.662

The p value associated with this result (p = .272) indicated there was not a
statistically significant association between diabetes status and AMD. The odds ratio
result was 1.258, with a 95% CI of .952 to 1.662, including 1, which means that there
was not a statistical significance indicating that people with diabetes in this sample were
not at higher risk for AMD than those without diabetes. Therefore, I left diabetes out of
the multivariate logistic regression analysis run for research question 6. Based on the
results found on the association between diabetes and AMD to answer this question, I
failed to reject the null hypothesis for research question 2.
Results for Research Question 3
To answer research question 3, “What is the association between age and
development of AMD?”, I utilized binary logistic regression using complex samples for
reported age and AMD that were extracted from the NHANES database. The study
population was N = 5,604. The NHANES dataset reported age on the entire study sample
of 5,604 with graded fundus photography. Table 9 contains the results from the binary
logistic regression.
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Table 9
Individual Binary Logistic Regression Results for Variable Age: Association with
Dichotomous Age-related Macular Degeneration
Characteristic

p

Odds Ratio

95% Confidence Interval
Lower
Upper

Age
≥ 60 vs. 40-59

≤.001

5.455

3.773

7.887

The p value result of <.001 indicated a statistically significant association between
age and AMD. The odds ratio result of 5.455 (95% CI: 3.773 to 7.887) suggested
individuals in the higher age category (aged 60 years and older) were 5.455 times more
likely to have AMD than their younger counterparts aged 40-59 years. Therefore, I
included age in the multivariate logistic regression analysis. I rejected the null hypothesis
for research question 3 (there is no association between age and the development of
AMD) based on the results found for this study.
Results for Research Question 4
To answer research question 4, “What is the association between race and the
development of AMD?”, I utilized binary logistic regression using complex samples for
reported race and AMD that were extracted from the NHANES database. The study
population was N = 5,604. The NHANES dataset reported race on the entire study sample
of 5,604 with graded fundus photography. Table 10 contains the results from the binary
logistic regression.
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Table 10
Individual Binary Logistic Regression Results for Variable Race/Ethnicity: Association
with Dichotomous Age-related Macular Degeneration
Characteristic
Race/Ethnicity
Other Hispanic vs.
Non-Hispanic White
Mexican American
vs. Non-Hispanic
White
Non-Hispanic Black
vs. Non-Hispanic
White
Other race vs. NonHispanic White

p

Odds Ratio

95% Confidence Interval
Lower
Upper

≤.001
.576

.341

.975

.670

.472

.950

.333

.227

.489

.608

.321

1.152

The p value result of <.001 indicated a statistically significant association between
race/ethnicity and AMD. The odds ratios presented in Table 10 utilized non-Hispanic
white as the referent. All results suggested that non-Hispanic whites were at higher risk
of AMD than the other groups. The odds ratio result of .576 (95% CI: .341 to .975) for
individuals of other Hispanic race/ethnicity suggested non-Hispanic whites were 1.73
times more likely to have AMD. The odds ratio result of .670 (95% CI: .472 to .950) for
individuals of Mexican American race/ethnicity suggested that their non-Hispanic white
counterparts were 1.49 times more likely to have AMD. The odds ratio result of .333
(95% CI: .227 to .489) for individuals of non-Hispanic black race/ethnicity also showed
that their non-Hispanic white counterparts were 3 times more likely to have AMD. The
odds ratio result of .608 (95% CI: .321 to 1.152) for individuals of other race
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race/ethnicity suggested non-Hispanic whites were 1.64 times more likely to have AMD.
I converted these odds ratios to suggest the increased risk for non-Hispanic whites when
compared to each of the other groups. I found race to be statistically significantly
associated with AMD and therefore I included race in the multivariate logistic regression
analysis. I rejected the null hypothesis for research question 4 (there is no association
between race and the development of AMD) based on the results found using this study
sample.
Results for Research Question 5
To answer research question 5, “What is the association between smoking
(current/past/non) and the development of AMD?”, I utilized binary logistic regression
using complex samples for smoking status and AMD that were extracted from the
NHANES database. The study population was n = 5,602. The NHANES dataset reported
smoking status on 5,602 individuals from the 5,604 participant study sample. Smoking
status data was missing or unreported for only 2 individuals. Table 11 contains the results
from the binary logistic regression.
Table 11
Individual Binary Logistic Regression Results for Variable Smoking Status: Association
with Dichotomous Age-related Macular Degeneration
Characteristic
Smoking status
Past vs. Non-smoker
Current vs. Nonsmoker

p

Odds Ratio

95% Confidence Interval
Lower
Upper

≤.001
1.584
.809

1.229
.569

2.048
1.151
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The p value result of <.001 indicated a statistically significant association between
smoking status and AMD. The odds ratio result for past smokers was 1.586 (95% CI:
1.229 to 2.048) when compared to non-smokers. These results indicate that past smokers
were 1.58 times more likely to have AMD than non-smokers. The odds ratio result for
current smokers was .809 (95% CI: .569 to 1.151) when compared to non-smokers
suggesting that current smokers are 1.23 times less likely to have AMD than nonsmokers. However, the confidence interval does cross 1, indicating that there was no
difference between current smokers and non-smokers when it comes to having AMD. I
found smoking status to be statistically significant; therefore, I included smoking status in
the multivariate logistic regression analysis. I rejected the null hypothesis for research
question 5 (there is no association between smoking status (yes/no) and the development
of AMD) based on the results found for this study.
Results for Research Question 6
To answer research question 6, “What is the association between vitamin D level
and the development of AMD, after controlling for covariates?”, I utilized a multivariate
logistic regression using complex samples for vitamin D level and AMD status after
including covariates age, race, and smoking status. I found all of the included covariates
to show statistical significance in each of their individual binary logistic regression
analyses. Based on the bivariate logistic results, I did not include diabetes in the model. I
included the entire study population in the multivariate analysis for a total of N = 5,604.
Results for this multivariate logistic regression are included in Table 12.
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Table 12
Multivariate Logistic Regression Results for the Association of Vitamin D Level with
Dichotomous Age-related Macular Degeneration after Controlling for Age,
Race/Ethnicity, and Smoking Status
Characteristic

p

Odds Ratio

95% Confidence Interval
Lower

Vitamin D (ng/ml)
1-9.99 vs. 20-29.99
10-19.99 vs. 20-29.99
≥30 vs. 20-29.99

Upper

.553
.454
.145
.156

.570
.969
.924

.255
.731
.683

1.271
1.284
1.249

Age ≥ 60 vs. 40-59

<.001

5.004

3.382

7.405

Race/Ethnicity

.011
.314

.738

.412

1.323

.198

.863

.591

1.262

.237

.430

.274

.675

.456

.647

.289

1.446

1.247
1.07

.943
.725

1.649
1.603

Other Hispanic vs. NonHispanic White
Mexican American vs.
Non-Hispanic White
Non-Hispanic Black vs.
Non-Hispanic White
Other race vs. NonHispanic White
Smoking status
Past vs. Non-smoker
Current vs. Non-smoker

.293
.144
.209

The p value result varied for each independent variable comparison to AMD
suggesting statistical significance in the multivariate model. For vitamin D, I found the p
value to be .553, not statistically significant. The results in the highest levels of vitamin D
(30+ ng/ml) had an odds ratio of .924 (95% CI: .683 to 1.249) when compared to 20-
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29.99 ng/ml. The odds ratio in the lowest level of vitamin D (1-9.99 ng/ml) was .570
(95% CI: .255 to 1.271) when compared to 20-29.99 ng/ml. The odds ratio for individuals
with 10-19.99 ng/ml of vitamin D was .969 (95% CI: .731 to 1.284) when compared to
individuals with 20-29.99 ng/ml of vitamin D. The confidence interval crosses 1 in all
three comparisons, indicating there was no difference between any of the groups.
I found the p value for age to be <.001 and statistically significant in the
multivariate model. For age, older individuals had an odds ratio of 5.004 (95% CI: 3.382
to 7.405), indicating individuals aged 60 years and older were 5 times more likely to have
AMD than their younger counterparts. I found age to be associated with AMD in both the
bivariate and multivariate models. This odds ratio result indicated little to no modifying
effect occurred when I added the other variables.
The p value result of .011 for association between race/ethnicity indicated
statistical significance. I found the odds ratio results for race/ethnicity to be .738 (95%
CI: .412 to 1.323) for ‘other Hispanic’, .863 (95% CI: .591 to 1.262) for ‘Mexican
American’, .430 (95% CI: .274 to .675) for ‘non-Hispanic black’, and .647 (95% CI: .289
to 1.446) for ‘other race’. These results indicated that (similar to the bivariate model)
non-Hispanic whites were more likely to have AMD than individuals in each race
category when included in the multivariate model.
For smoking, I found the p value to be .293 and was not statistically significant in
the multivariate model. For past smokers, the odds ratio result was 1.247 (95% CI: .943
to 1.649) when compared to non-smokers indicating that past smokers are 1.247 times
more likely to have AMD, but it was not statistically significant. The odds ratio result for
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current smokers was 1.078 (95% CI: .725 to 1.603) when compared to non-smokers. I
failed to reject the null hypothesis for research question 6 (there is no association between
vitamin D level and the development of AMD after controlling for covariates) based on
the results found for this study. I compared the six models, the five univariate logistic
regressions, and the multivariate logistic regression using Pseudo R2 and present them in
Table 13.
Table 13
Cox and Snell Pseudo R2, Nagelkerke Pseudo R2, McFadden Pseudo R2 Values by Model
Model
Univariate
Vitamin D
Diabetes
Age
Race/Ethnicity
Smoking status
Multivariate

Cox and Snell

Nagelkerke

McFadden

.001
.000
.040
.005
.004
.043

.002
.001
.104
.013
.011
.110

.002
.001
.084
.010
.009
.089

Cox and Snell R2, Nagelkerke R2, and McFadden R2 values (sometimes referred to
as Pseudo R2 values) are methods of calculating explained variation and I utilized these to
compare models. I included these in the analysis to understand which model fits the best
in relation to the other models. The Cox and Snell, Nagelkerke, and McFadden pseudo R2
values for vitamin D ranged from .001 to .002, for diabetes ranged from .000 to .001, for
age ranged from .040 to .104, for race ranged from .005 to .013, and for smoking status
ranged from .004 to .011. In the multivariate model, the Cox and Snell, Nagelkerke, and
McFadden pseudo R2 values ranged from .043 to .110. This means that all variables
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combined explained 4.3% to 11% of the variance in the model and the majority of the
variance was explained by age. In addition, this indicated that the multivariate model was
an improved model compared to the bivariate models. As I expected, the multivariate
model demonstrated that it was the best model by having the highest pseudo R2 values.
These results demonstrate that the multivariate model provided the best fit, though it was
not predictive of AMD.
Summary
Based on the results found from the analysis in this study, I failed to reject the
null hypotheses from the individual research questions 1 (there is no association between
vitamin D level (high versus low) and the development of AMD) and research question 2
(there is no association between diabetes (yes/no) and the development of AMD). I
rejected the null hypotheses for research questions 3, 4, and 5. I concluded that there were
statistically significant associations between age, race, and smoking status in individual
comparisons to AMD status. I failed to reject the null hypothesis for research question 6
(there is no association between vitamin D level and the development of AMD after
controlling for covariates) because results indicated that there was not a statistically
significant association (p = .553) between vitamin D level and presence of AMD in
participants when controlling for covariates age, race, and smoking status.
In Chapter 5, I discuss and interpret the results described in Chapter 4. I interpret
these results in the context of existing theories based on the current literature on the topic
of vitamin D association to AMD. In addition, I review the strengths and limitations of
the current study. In Chapter 5, I summarize the findings of the study, propose
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recommendations for further research on the topic based on the findings, and last review
the potential affect this research study will have on social change.
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Chapter 5: Discussion
Introduction
In this cross-sectional study, I utilized the NHANES existing database to evaluate
the association between vitamin D and AMD, while also examining the association
between covariates diabetes, age, smoking status, and race independent of AMD. I found
covariates age, race, and smoking status to be statistically significant and I included them
in a multivariate model testing association between vitamin D and AMD. In Chapter 5, I
provide interpretations of the data findings, review limitations of the study, discuss
recommendations based on the findings, provide implications for social change, and, last,
provide conclusions to the study.
Interpretation of the Findings
Overall, the results from this study failed to suggest an association between
vitamin D levels to AMD is present with or without the covariates included in the model.
There was not an association found between vitamin D level and presence of AMD. I
found an association between age, smoking, and race to presence of AMD in each of the
bivariate models. Age and race still had an association in the multivariate model.
However, the smoking association was no longer present in the multivariate model.
Running the pseudo R2 tests provided a better understanding of how much variation in the
dependent variable can be explained by the model. The 4.3% to 11% variance results of
the pseudo R2 test demonstrated that age was the main variable that explained the
variance. The other variables contributed a minor percentage (1% or less) to the model.
When running the multivariate model, the assumption was that the multivariate model

67
would demonstrate higher pseudo R2 numbers than each of the individual models. This
was confirmed in the results found for this analysis. These results suggested that once the
additional variables of age, smoking status, and race were all added to the model, it
created a better model.
Vitamin D and AMD
In this study, I did not find vitamin D to be statistically significantly associated to
presence of AMD, even after controlling for covariates. There were not enough patients
to do an analysis including late AMD. Therefore, I combined early and late AMD as any
AMD for the analysis. In this cross-sectional study of 5,604 individuals aged 40 years
and older, only 7.9% of the population had any form of AMD and only 31.6% of the
population had low levels of vitamin D. Vitamin D levels were broken down into the
following four categories for the analysis: 1–9.99 ng/ml, 10–19.99 ng/ml, 20–29.99
ng/ml, and 30+ ng/ml. The reference category for this analysis was 20–29.99 ng/ml,
based on the normal range for vitamin D level and this category had the largest number of
individuals in the study sample (n = 2,049).
A statistically significant association between vitamin D level and AMD was not
found in either the bivariate or multivariate models. In the multivariate model, vitamin D
was found to have a p value result of .553 (not statistically significant). The results in the
highest levels of vitamin D (30+ ng/ml) had an odds ratio of .924 (95% CI: .683 to 1.249)
when compared to 20–29.99 ng/ml. The odds ratio in the lowest level of vitamin D (1–
9.99 ng/ml) was .570 (95% CI: .255 to 1.271) when compared to 20–29.99 ng/ml. The
odds ratio for individuals with 10–19.99 ng/ml of vitamin D was .969 (95% CI: .731 to
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1.284) when compared to individuals with 20–29.99 ng/ml of vitamin D. The confidence
interval crosses 1 in all three comparisons, suggesting there is no difference between any
of the groups.
In the bivariate analysis, the odds ratio in the lowest level of vitamin D (1-9.99
ng/ml) was .409 (95% CI: .209 to .801) when compared to 20-29.99 ng/ml. The odds
ratio for individuals with vitamin D level 10-19.99 ng/ml was .858 (95% CI: .631 to
1.168) when compared to individuals with 20-29.99 ng/ml. The highest levels of vitamin
D (30+ ng/ml) had the highest odds ratio of 1.001 (95% CI: .758 to 1.323) when
compared to 20-29.99 ng/ml. The odds ratio went up as vitamin D level went up.
However, these results suggested that overall vitamin D level was not predictive of
AMD. The only comparison where the confidence interval did not cross 1 was in the
lowest level (1-9.99 ng/ml) compared to 20-29.99 ng/ml. Vitamin D serum
concentrations may fluctuate throughout the year or by season and this was not taken into
account in the current study.
The results from the current study provided similar findings (of no association of
vitamin D status to AMD) to what the most recent similar cross sectional study by
Cougnard-Gregoire and colleagues (2015) found. The latter study included 697
individuals from an elderly population (aged 72.7 + 4.4 years) in Bordeaux France
(Cougnard-Gregoire et al., 2015), considerably less than the current study sample of
5,604. Cougnard-Gregoire and colleagues (2015) classified AMD as early or late instead
of presence or no presence of AMD. The current study did not contain a high prevalence
of vitamin D deficiency like the study by Cougnard-Gregoire and colleagues (2015) that
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observed 83.2%. It is possible that because only 31.6% of the population had low levels
of vitamin D (<19.99ng/ml) and 3.2% of those had extremely low levels (<9.9 ng/ml),
that it played a role in whether a signal was observed.
Results from the current study conflict with the results from the cross-sectional
study conducted by Itty and colleagues (2014) which found a statistically significant
association when comparing vitamin D levels in individuals with NVAMD (late AMD) to
those with NNVAMD (early AMD) and controls. Late AMD was very rare in the current
NHANES study and therefore the early and late AMD individuals needed to be
combined. It is possible that had the numbers been larger that an association may have
been observed and there were not enough participants to show an affect.
The current study utilized data from NHANES that did not provide information of
whether blood samples were taken during different times of the year. NHANES data also
does not provide information of location/latitude of participants or source of vitamin D. A
breakdown of latitude of individuals that participated in the study would have provided a
better understanding of potential for gaining vitamin D source from sunlight. The study
sample size of 5,604 was powered to detect a weak association with a power of 90% and
an odds ratio of 1.2. Therefore, it was not likely that the negative study findings were due
to a type II error.
Diabetes and AMD
In the current study, I did not find diabetes to be statistically significantly
associated to presence of AMD as a single predictor. The p value result was .272 with an
odds ratio of 1.258 (95% CI: .952 to 1.662) indicating there was not a statistically
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significant association between diabetes status and AMD. In the current study, I found
that people with self-reported diabetes in this sample were not at higher risk for AMD
than those without diabetes. Therefore, I left diabetes out of the multivariate model.
Diabetes disease in the eye involves microvascular complications and has been
studied as a potential risk factor to association for development of AMD in the AREDS
study and Blue Mountains Eye Study (Tomany et al., 2004; AREDS 2005). The AREDS
study (2005) found a weak association of diabetes as a risk factor to AMD based on
medical history that reported the individual was under treatment for diabetes. The Blue
Mountains Eye Study found having diabetes to be associated with the development of
incident GA, a different form of AMD than was studied here (Tomany et al., 2004).
Diabetes as a risk factor for AMD has limited data behind it and studying this covariate
offered the greatest potential to add the existing literature on this topic. However, the
results from the current study did not offer a finding to support a weak association or an
association at all. There is still an opportunity to examine this association further in other
ways. Perhaps using medical records with physician diabetes diagnosis information
would be another approach to evaluate this association further.
Age and AMD
In this study, I found age to be statistically significantly associated to the presence
of AMD in both the bivariate and multivariate models. The p value result for age was
<.001 in both the bivariate and multivariate models. The odds ratio result was 5.455 (95%
CI: 3.773 to 7.887) in the bivariate model and 5.004 (95% CI: 3.382 to 7.405) indicating
there was a statistically significant association between age and AMD, where individuals
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60 years of age and older were 5 times more likely to have AMD than individuals aged
40-59 years of age in both models. The age p value was similar in both models whereas
the p value for other variables vitamin D and smoking status changed. It is likely that age
had a modifying effect on these other variables. I discuss in further detail in those
sections.
The findings reported from the current study regarding age were similar and
consistent with results in the existing literature from previous studies testing this
association. The current study findings results were not surprising, as age has been well
established as a predictor for AMD in multiple large population based studies such as the
AREDS study, the Beaver Dam Eye study, the Blue Mountains Eye study, and the
Rotterdam study. All of these studies included age as a risk factor in 1,000’s of
individuals and found increasing age to be a strong risk factor to development of AMD
(Chew et al., 2014; Friedman et al., 2004; AREDS, 2000). As such, the term age is now
included in the AMD disease name.
Race and AMD
In this study, I found race/ethnicity to be statistically significantly associated to
the presence of AMD in both the bivariate and multivariate models. The p value result for
race/ethnicity was <.001 in the bivariate model and .011 in the multivariate model. The
odds ratio and confidence interval results for each race and ethnicity category compared
to non-Hispanic whites suggested a statistically significant association between each race
category and AMD. Non-Hispanic whites were 1.49–3 times more likely to have the
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presence of AMD than other Hispanics, Mexican Americans, non-Hispanic blacks, and
other race categories.
The findings of the current study confirmed what multiple other large population
based studies have found suggesting non-Hispanic whites are at the greatest risk for
developing AMD. The Beaver Dam Eye study, the Blue Mountains Eye study, the
Rotterdam study, and the AREDS study have studied race as a risk factor in 1,000’s of
individuals and found whites to be more likely to develop AMD (Chew et al., 2014;
Friedman et al., 2004; AREDS, 2000). The Eye Diseases and Prevalence Research Group
have reported Hispanics to have the lowest rate of AMD when compared to white and
black counterparts (Friedman et al., 2004). In contrast, the current study found nonHispanic blacks to have the lowest likelihood of having AMD to all other race categories.
In the current study ‘Mexican American’ (15.4 % of the study population) and ‘other
Hispanic’ (7.2% of the study population) were labeled separately. It is important to
consider how it might have affected the results as they compare to ‘non-Hispanic blacks’
(20.3% of the study population) if they had been combined together. In the multivariate
model, the results were similar with a statistically significant finding suggesting that nonHispanic whites were at the greatest risk for AMD. The multivariate results did not
appear to be modified by the other covariates.
Smoking and AMD
In this study, I found smoking to be statistically significantly associated to the
presence of AMD in the bivariate model, but not the multivariate model. In the bivariate
model, the odds ratio was 1.586 (95% CI: 1.229 to 2.048) for past smokers when

73
compared to non-smokers. The odds ratio was .809 (95% CI: .569 to 1.151) for current
smokers when compared to non-smokers. These results suggested that past smokers were
1.58 times more likely to have AMD than non-smokers and current smokers are 1.23
times less likely to have AMD than non-smokers. The confidence interval for the past
smokers comparison did not include 1 suggesting that smoking was predictive of AMD.
The bivariate results confirmed previous findings from the AREDS study suggesting
smoking is a risk factor for AMD. However, findings in this study indicating past
smokers were at higher risk for having AMD than current smokers differed from the
findings of Chew and colleagues (2014) and Tomany and colleagues (2004) of the
inverse where current smokers were at higher risk than past smokers of having AMD.
In the multivariate model, the p value for smoking comparison to AMD went up
to .283 (losing statistical significance) indicating the other variables in the model had a
modifying effect on smoking. Age was most likely the variable that had the most effect
on the multivariate model as I found age to be the strongest predictor of AMD. The
pseudo R2 tests showed the multivariate model as the strongest with a range from .043 to
.110. Age had the next highest values with a range from .040 to .104 and was found to
have the highest pseudo R2 values of all of the individual models. These findings indicate
that age was the most predictive of AMD and provided the strongest model behind the
multivariate model potentially modifying the other variables.
The life course epidemiology model was utilized as the theoretical framework for
this study. I found a history of past smoking to be associated with development of AMD.
How smoking through the course of an individual’s life affects AMD disease
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development was represented in this comparison. The smoking variable demonstrated
how the life course theory plays a role in studying disease development. Age as a
modifying factor played a role in how the smoking variable had a potential to change in
the multivariate model further demonstrating how other factors have modifying effects on
one another.
Limitations of the Study
Limitations of the study include: not understanding the source of vitamin D (food,
supplements, sun exposure), self-reports of data, small number of participants that have
AMD compared to non-AMD, small percentage of participants with low vitamin D and
even smaller percentage with extremely low (deficient) vitamin D, and differing vitamin
D level measurements between 2-year datasets. Understanding the source of vitamin D
would allow for better understanding of the current versus past state of vitamin D status.
For example, if vitamin D levels were attributed from use of supplements, then perhaps
vitamin D level would have recently changed thereby making it difficult to ascertain an
association to the affect of presence or absence of disease.
Individual participant bias for the self-reported data variables included smoking
and diabetes. Smokers may have provided answers they felt were more socially
acceptable and therefore contributed to bias in the study. In addition, when answering
specifics about smoking habits, memory recall may not have been accurate also
contributing to bias. A more accurate data collection method for diabetes status would
have been to collect medical records for participants in the study rather than to collect
data by asking participants to self-report. This is another potential limitation of the study
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because it contributed to potential bias. AMD by definition is a disease of older
individuals and increases potential recall bias due to worse memory recall in the aging
population.
Race as a covariate is straightforward and should not have contributed to bias that
influenced outcomes. The method of data collection for both the independent variable
(vitamin D level) and dependent variable (stage of AMD) were collected in a manner that
minimized recall bias. Those methods included vitamin D testing done in a lab and
reading of retinal images that were performed by masked readers (NHANES, 2015).
However, the lab method for vitamin D measurement changed from the 2005–2006 and
2007–2008 data collection years (as discussed in more detail in Chapter 3), which
presented a potential limitation through measurement bias. In addition, source of vitamin
D from food, supplements, or amount of sun exposure was not estimated, which may
have influenced the results.
Recommendations
A recommendation based on the findings from this study is to attempt to better
understand the diabetes to AMD association. Future researchers should consider using
physician medical records with diagnosis information as an alternative approach to
evaluate this association further. Of all of the variables studied here, diabetes is the least
studied in terms of association to AMD. Age, smoking status, and ethnicity are well
established at this point. The body of literature on vitamin D association to AMD is still
growing, but it appears that the evidence remains unclear. The data from this study and
the literature have provided conflicting results. Additional research on this topic should
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continue with considerable thought on how to strengthen studies with large AMD
populations. This study did not evaluate the association broken down by early and late
AMD and further research with large enough numbers to evaluate both will be important.
The number of NVAMD (late AMD) individuals has been small in the previous studies
and provides an opportunity for further exploration. Perhaps finding a population to study
with large numbers of individuals in higher age categories that are more likely to have
advanced disease would be beneficial.
Implications for Social Change
The findings from this study could be used for positive social change by
encouraging medical and public health agencies to target screening programs at high-risk
age, smoking, and race groups. There remains to be conflicting data in the literature. This
study adds to the body of literature suggesting that higher levels of vitamin D are not
necessarily beneficial. There has been an increase in the community recommending more
focus on and testing of vitamin D levels. The associated emphasis has been on
maintaining increased vitamin D levels for health benefits. Perhaps it is not the case when
evaluating AMD risk and vitamin D is not as closely associated with AMD as the
thinking was trending toward. However, this study does confirm previous findings of age,
race, and smoking status association to AMD. Health care professionals can use this
information to target screening for AMD among at-risk groups. Perhaps AMD screenings
among older, white individuals would be beneficial. Since an association was also not
found between diabetes and AMD, perhaps more research needs to be conducted on this
topic as the numbers of individuals with diabetes continues to grow.
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Conclusion
This study attempts to better understand the association between vitamin D and
AMD in a large weighted sample from the publicly available NHANES dataset that is
representative of the U.S. population. The study fails to find an association between
vitamin D and AMD. Covariates that are included in the analysis are diabetes, age, race,
and smoking status. Age is strongly predictive of AMD and has an affect on the
multivariate model.
The findings from this study conducted from a large population sample
representative of the U.S. population adds to the literature on the topic of vitamin D
association to AMD. The results of this study do not support an inverse association of
vitamin D to AMD and fails to support a specific role for vitamin D in AMD. It is still
unknown whether vitamin D supplements, a diet rich in vitamin D, or safe exposure to
the sun would play a role in development of AMD.
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